Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cardiff Oncology ( (CRDF) ) has issued an announcement.
Cardiff Oncology has outlined new clinical data and development plans for its PLK1 inhibitor onvansertib, highlighting strong efficacy signals in first-line RAS-mutant metastatic colorectal cancer, including a 72% confirmed overall response rate and favorable progression-free survival trends when combined with FOLFIRI and bevacizumab. The company is positioning onvansertib as a potential blockbuster therapy uniquely designed for the RAS-mutated mCRC population and plans to meet with the FDA in the first half of 2026 to review a proposed registrational program using a 30 mg dose, which, if successful, could significantly reshape treatment options in a large, underserved oncology market.
The most recent analyst rating on (CRDF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.
Spark’s Take on CRDF Stock
According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.
The score is primarily weighed down by weak financial performance (minimal revenue, large losses, and sustained cash burn with declining equity), reinforced by bearish-to-soft technicals (below key moving averages and negative MACD). Valuation is hard to assess due to negative earnings and no dividend, while the leadership transition provides a modest positive offset but comes with execution risk.
To see Spark’s full report on CRDF stock, click here.
More about Cardiff Oncology
Cardiff Oncology, Inc. is a clinical-stage oncology company focused on developing targeted cancer therapies, with a lead emphasis on metastatic colorectal cancer. Its primary product candidate, onvansertib, is an oral, highly selective PLK1 inhibitor aimed at RAS-mutated malignancies, particularly first-line RAS-mutant metastatic colorectal cancer, an area with limited innovation and no approved targeted therapies in the U.S.
Average Trading Volume: 1,227,541
Technical Sentiment Signal: Sell
Current Market Cap: $114.5M
For an in-depth examination of CRDF stock, go to TipRanks’ Overview page.